title: Effect of growth hormone on dawn phenomenon in patients with type 2 diabetes.
abstract: We aimed to investigate the involvement of growth hormone in dawn phenomenon and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). On six occasions separated by intervals of at least 3 days, subjects received early evening (16:00 hours) or late night (23:00 hours) pretreatment with subcutaneous injection of normal saline, human growth hormone, or octreotide. Modified euglycemic insulin clamp test was done 16 hours later and variable glucose infusion (M values) was determined. Plasma glucose, serum insulin, insulin-like growth factor-1, non-esterified fatty acids, and metabolic clearance rate of insulin (MCRI) were measured. Early evening application of growth hormone decreased MCRI 16 hours later, suggesting reduction in insulin sensitivity. Exogenous growth hormone injection reduced insulin sensitivity in T2DM patients. Results provide direct evidence for the role of growth hormone in regulating the insulin sensitivity in insulin-resistant patients.
authors: Division of Endocrinology and Metabolism, Department of Medicine, Taipei-Veterans General Hospital, Taipei 112, Taiwan.
authors: Kuang-Chung
authors: KC
authors: Shih
authors: Sheng-Hwu
authors: SH
authors: Hsieh
authors: Ching-Fai
authors: CF
authors: Kwok
authors: Chii-Min
authors: CM
authors: Hwu
authors: Po-Shiuan
authors: PS
authors: Hsieh
authors: Low-Tone
authors: LT
authors: Ho
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D055870:Drug Chronotherapy; D005260:Female; D015309:Glucose Clamp Technique; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000097:blood* / Q000494:pharmacology*; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D015282:Octreotide / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D019382:Human Growth Hormone; D015282:Octreotide